An observational study in Acute Kidney Injury, Renal Insufficiency, Chronic and Heart Failure, sponsored by University of Texas Southwestern Medical Center. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by University of Texas Southwestern Medical Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 370 studies in Acute Kidney Injury with a site in United States — 72 open to participants now, 88 under way, 9 of them phase 3. Acute Kidney Injury · United States.
Among the 370 studies in Acute Kidney Injury with a site in United States, this one is the 88th largest by enrollment of the 131 observational ones that give a count, is one of 18 that started in 2016, is one of 132 observational ones, and was the 140th registered.
1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.
Browse Acute Kidney Injury studies →72 of the 370 studies in Acute Kidney Injury with a site in United States are open now. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 18+
University of Minnesota · Sites in United States
Ages 30–75
University of California, San Francisco · Sites in United States
Ages 18+
Bassett Healthcare · Sites in United States
Ages 18+
Dana Fuhrman · Sites in United States
Ages up to 18
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
370 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 26 · Phase 2 69 · Phase 3 29 · Phase 4 23
First in 1999; this study’s year is marked. 18 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 61 is below the median of 160 across 814 observational studies indexed under Acute Kidney Injury.
Median enrollment 67 across the 237 interventional studies, 124 across the 131 observational. Of the 240 that completed or were terminated, 84 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
97 of 370 have an industry lead sponsor. The 10 most frequent:
University of Texas Southwestern Medical Center is the lead sponsor of 1,012 studies on the registry; 200 are open to participants now.
Of its 139 completed or terminated interventional studies of FDA-regulated products, 105 (76%) have results posted.
University of Texas Southwestern Medical Center has 1 study filed under Acute Kidney Injury — fewer than ten, so there is no comparison to draw.
33 of the studies in Acute Kidney Injury with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07161843Phase 3Ebima Clifford OkundayeUse of QRX3 for Acute Tubular Necrosis Type of Renal Failure in Hospitalized Patients ( QRX-3 in ARF) | 2026-12-30 |
| NCT05399537Phase 3Vantive Health LLCSafety Evaluation of Prismocitrate 18 in Patients Receiving CRRT | 2027-01 |
| NCT05084196Phase 3Rutgers, The State University of New JerseyMelatonin for Prevention of Kidney Injury | 2027-06-01 |
| NCT07001098Stanford UniversityAmino Acids for Cardiac Surgery Associated AKI | 2026-11 |
| NCT07016074University of MichiganInorganic Nitrate (NaNO3) Prevention of Contrast-Associated Acute Kidney Injury | 2026-11-30 |
Add all 33 to your calendar (.ics) → With an account.
Among the 370 studies in Acute Kidney Injury with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In the last decade, transcatheter aortic valve replacement (TAVR) has become an increasingly utilized alternative procedure for replacing a stenotic aortic valve. This study collects clinical information, DNA, blood and urine samples (throughout procedural hospitalization) in order to investigate the incidence of acute kidney injury (AKI) in patients undergoing TAVR and to identify key clinical and procedural predictors of AKI. This study seeks to identify blood and urine biomarkers that can be used for early detection of AKI around the time of the procedure. The study seeks to assess for novel genetic variants associated with development of AKI after TAVR. Finally the study seeks to assess for novel genetic variants and biomarkers that are associated with adverse cardiovascular events after TAVR and to further explore how these events may inter-relate with acute kidney injury.
This study enrolls patients who have aortic stenosis who undergo TAVR at the University of Texas Southwestern Medical Center University Hospital. Development of post-TAVR AKI defined according to the Kidney Disease: Improving Global Outcomes (KDIGO) SCr based criteria will be ascertained. Patients will be followed during primary hospitalization and during the 5 years following TAVR for adverse kidney outcomes as well as potentially related adverse cardiovascular outcomes. Clinical and procedural data is collected for each study patient. All subjects will have paired blood and urine collection done pre-TAVR, 6 hours after aortic valve prosthesis deployment, and on post-procedure days 1 and 2. Subjects who develop AKI will also have paired blood and urine samples collected on days 3, 4 and 5. Patients receive follow-up questionnaires by mail or email asking about hospitalizations as well as visits to cardiology, nephrology and primary care physicians. Questionnaires will also ask about health-related quality of life using validated study questionnaires. Patient follow-up will occur at regular intervals until 5 years after TAVR procedure.
Subjects will be enrolled from the population of patients with aortic stenosis undergoing TAVR. Enrollment will likely occur over a 15 year time period to reach target enrollment. A total of 3,000 subjects are presently targeted for enrollment at University of Texas Southwestern University Hospitals and Parkland Health and Hospital Systems.
Inclusion criteria: Subjects are eligible to participate if they are undergoing TAVR for aortic stenosis at the University of Texas Southwestern Medical Center.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The group of interest is the patient population with aortic stenosis who are undergoing transcatheter aortic valve replacement (TAVR)
Procedure: Transcatheter Aortic Valve Replacement
The investigators will collect blood and urine samples from patients with aortic stenosis who are undergoing transcatheter aortic valve replacement.
Acute Kidney Injury using KDIGO criteria
Data will be collected from electronic medical records; data points to be collected for this measurement include serum creatinine
Time frame: Day of procedure to post procedure day 5
Chronic renal insufficiency (i.e. number of patients that will have received a diagnosis of chronic renal insufficiency)
Chronic renal insufficiency is defined as patient having impaired renal function (albumin/creatinine ratio \>/= 300 mg/g and eGFR \<60 mL/min/1.73\^2).
Time frame: Day of procedure to year 5
Heart failure per NYHA class II, III, IV
This will be measured in accordance to New York Heart Association Guidelines.
Time frame: Day of procedure to year 5
Presence of Arrhythmia (i.e. number of patients who develop an arrhythmia from postoperative day 0 to 5 years).
Data will be collected from electronic medical records; data points to be collected for this measurement include post-procedural EKG reports and progress notes.
Time frame: Day of procedure to year 5
Myocardial Infarction (i.e. number of participants who develop a MI during postoperative day 0 to year 5)
Data will be collected from electronic medical records; data points to be collected for this measurement include post-procedural EKG reports, cardiac enzyme values, progress notes, and cardiac catheterization reports.
Time frame: Day of procedure to year 5
Cerebrovascular accident (i.e. number of participants who develop transient ischemic attack or permanent stroke during postoperative day 0 up to 5 years)
Data will be collected from electronic medical records; data points to be collected for this measurement include post procedural imaging data and progress notes.
Time frame: Day of procedure to year 5
Vascular complications (i.e. number of participants who develop arterial injury, dissection, limb ischemia during postoperative day 0 up to year 5)
Data will be collected from electronic medical records; data points to be collected for this measurement include post procedural imaging data, progress notes and operative reports.
Time frame: Day of procedure to year 5
Need for dialysis (e.g. number of participants who undergo post-procedural dialysis)
Data will be collected from electronic medical records; data points to be collected for this measurement include progress notes, and consultation notes.
Time frame: Day of procedure to year 5
Mortality (i.e. number of participants who are deceased during postoperative day 0 up to year 5)
Data will be collected from electronic medical records; data points to be collected for this measurement include progress notes and death notes.
Time frame: Day of procedure to year 5
KCCQ Quality of Life Survey
The Kansas City Cardiomyopathy Questionnaire (KCCQ Short Form) is a health-related quality of life measure for heart failure.
Time frame: Administered once prior to the procedure and 1 month to 5 years after hospital discharge
SAQ Quality of Life Survey
The Seattle Angina Questionnaire (SAQ Short Form) is a health-related quality of life measure for coronary artery disease.
Time frame: Administered once prior to the procedure and 1 month to 5 years after hospital discharge
SF12 Quality of Life Survey
12-item short form Health survey (SF12) is a health-related quality of life measure of functional health and well-being from the patient's point of view.
Time frame: Administered once prior to the procedure and 1 month to 5 years after hospital discharge
Plan to share: Yes — There is a possibility that individual participant data and samples will be de-identified and shared with other cohort study investigators for purposes of replicating biomarker and genetic associations with adverse outcomes.
Supporting information: Statistical analysis plan, Clinical study report
Time frame: Data will become available at the discretion of the sponsor/Dr. Fox. Once enough data has been gathered and analyzed, and the need or DUA requests from other cohort researchers is received.
Access criteria: Data will be collected in REDCap, a data management tool used primarily for research and QI. It is a secure, HIPAA-compliant web application. Content is backed up offsite nightly and hosted in a secure environment maintained by UTSW Information Resources. Other cohort researchers will access survey questionnaires via the secure and confidential REDCap webpage with specific view only access. Patient confidentiality is of paramount importance. Data sent outside of UTSW will be de-identified or coded. The "key" to the code (i.e. patient identifying information) will not be provided to the recipient unless a limited dataset is approved for sharing via a data use agreement between Dr. Fox/UTSW and the recipient scientist/recipient scientist's institution.
Ran from Oct 2016 to primary completion in Dec 2024, 97 months.
Of 350 non-industry observational studies under Acute Kidney Injury, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's 97 months is above that.
Counting every sponsor, half of 365 studies reached it within 24 months; a quarter within 12 and three quarters within 42.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Mar 2031 → Dec 2024 and completion Mar 2031 → Dec 2024.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Texas Southwestern Medical Center →